Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jayesh Desai

Showing results (131-140 of 179) with videos related to

Pageof 18
Sort By:
The New England Journal of Medicine|May 30, 2025
Encorafenib, Cetuximab, and mFOLFOX6 in <i>BRAF</i>-Mutated Colorectal CancerElena Elez, Takayuki Yoshino, Lin Shen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 14, 2025
Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical TrialsJia Liu, Max Farrow, Lesley Seymour, et al.
Lancet (London, England)|October 19, 2006
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trialGeorge D Demetri, Allan T van Oosterom, Christopher R Garrett, et al.
Nature Medicine|October 19, 2025
YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trialTimothy A Yap, David J Kwiatkowski, Ibiayi Dagogo-Jack, et al.
Cancer|November 16, 2020
Long-term outcomes of pexidartinib in tenosynovial giant cell tumorsHans Gelderblom, Andrew J Wagner, William D Tap, et al.
BMC Cancer|June 2, 2016
ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumoursEva Segelov, Paul Waring, Jayesh Desai, et al.
Cancer|November 12, 2024
A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinibJayesh Desai, Andrew J Wagner, Irene Carrasco Garcia, et al.
Cell Death & Disease|March 1, 2024
BCL-X<sub>L</sub> inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF<sup>V600E</sup> colorectal cancerLaura J Jenkins, Ian Y Luk, Fiona Chionh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 13, 2024
Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic MalignanciesJason J Luke, Karen Gelmon, Lillian L Siu, et al.
JCO Precision Oncology|August 29, 2024
Patient Experience of Complex Genomic Sequencing Exploring Patient Preference, Barriers, and Enablers for DeliveryKortnye Smith, Sophie O'Haire, Benjamin Markman, et al.
Pageof 18

Showing results (131-140 of 179) with videos related to

Sort By:
Pageof 18
The New England Journal of Medicine|May 30, 2025
Encorafenib, Cetuximab, and mFOLFOX6 in <i>BRAF</i>-Mutated Colorectal CancerElena Elez, Takayuki Yoshino, Lin Shen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 14, 2025
Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical TrialsJia Liu, Max Farrow, Lesley Seymour, et al.
Lancet (London, England)|October 19, 2006
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trialGeorge D Demetri, Allan T van Oosterom, Christopher R Garrett, et al.
Nature Medicine|October 19, 2025
YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trialTimothy A Yap, David J Kwiatkowski, Ibiayi Dagogo-Jack, et al.
Cancer|November 16, 2020
Long-term outcomes of pexidartinib in tenosynovial giant cell tumorsHans Gelderblom, Andrew J Wagner, William D Tap, et al.
BMC Cancer|June 2, 2016
ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumoursEva Segelov, Paul Waring, Jayesh Desai, et al.
Cancer|November 12, 2024
A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinibJayesh Desai, Andrew J Wagner, Irene Carrasco Garcia, et al.
Cell Death & Disease|March 1, 2024
BCL-X<sub>L</sub> inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF<sup>V600E</sup> colorectal cancerLaura J Jenkins, Ian Y Luk, Fiona Chionh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 13, 2024
Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic MalignanciesJason J Luke, Karen Gelmon, Lillian L Siu, et al.
JCO Precision Oncology|August 29, 2024
Patient Experience of Complex Genomic Sequencing Exploring Patient Preference, Barriers, and Enablers for DeliveryKortnye Smith, Sophie O'Haire, Benjamin Markman, et al.
Pageof 18